Compare · MNMD vs ONCR
MNMD vs ONCR
Side-by-side comparison of Mind Medicine (MindMed) Inc. (MNMD) and Oncorus Inc. (ONCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MNMD and ONCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MNMD has more recent analyst coverage (16 ratings vs 0 for ONCR).
- Company
- Mind Medicine (MindMed) Inc.
- Oncorus Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- +19.56%
- -
- 1Y return
- +27.65%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 16
- 0
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Oncorus Inc.
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest MNMD
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)
- Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)
- SEC Form 144 filed by Mind Medicine (MindMed) Inc.
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- MindMed Announces New Employee Inducement Grant
- MindMed Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Latest ONCR
- SEC Form DEFA14A filed by Oncorus Inc.
- SEC Form 15-12G filed by Oncorus Inc.
- SEC Form DEFA14A filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Leadership Update, Other Events, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form RW filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update